Sartorius Stedim Biotech S.A. (EPA: DIM)

Sartorius Stedim Biotech Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	44,737	45,351	42,885	28,508	26,010	27,189
Revenue Growth (YoY)	-1.56%	5.75%	50.43%	9.60%	-4.34%	4.77%
Impairment of Goodwill	-2	-2	-69	10.8	-44.1	-1.6
Pretax Income	1,969	1,869	1,496	900.7	365.4	1,171
Income Tax Expense	499	511	420	345.8	137	298.5
Earnings From Continuing Operations	1,470	1,358	1,076	554.9	228.4	872.5
Earnings From Discontinued Operations	-21	-24	-78	-	-19.9	-111.9
Net Income to Company	1,449	1,334	998	554.9	208.5	760.6
Minority Interest in Earnings	-384	-397	-282	-150.6	-119.7	-135.7
Net Income	1,065	937	716	404.3	88.8	624.9
Preferred Dividends & Other Adjustments	-	-	-	-	-	5.5
Net Income to Common	1,065	937	716	404.3	88.8	619.4
Net Income Growth	6.18%	30.87%	77.10%	355.29%	-85.79%	41.83%
Shares Outstanding (Basic)	709	705	688	593	555	553
Shares Outstanding (Diluted)	738	731	714	618	580	579
Shares Change (YoY)	2.62%	2.38%	15.53%	6.57%	0.24%	0.45%
EPS (Basic)	1.50	1.33	1.04	0.68	0.16	1.12
EPS (Diluted)	1.43	1.28	1.00	0.65	0.16	1.07
EPS Growth	3.04%	27.62%	53.96%	317.52%	-85.40%	64.23%
Free Cash Flow	1,782	1,865	1,364	1,418	1,116	1,412
Free Cash Flow Per Share	2.41	2.55	1.91	2.30	1.93	2.44
Dividend Per Share	1.250	1.250	1.120	1.000	0.700	0.500
Dividend Growth	11.61%	11.61%	12.00%	42.86%	40.00%	-45.65%
Profit Margin	2.38%	2.07%	1.67%	1.42%	0.34%	2.28%
Free Cash Flow Margin	3.98%	4.11%	3.18%	4.98%	4.29%	5.19%
EBITDA	5,200	5,309	4,965	3,093	2,513	3,109
EBITDA Margin	11.62%	11.71%	11.58%	10.85%	9.66%	11.43%
D&A For EBITDA	2,328	2,497	2,487	1,667	1,553	1,616
EBIT	2,872	2,812	2,478	1,426	959.7	1,493
EBIT Margin	6.42%	6.20%	5.78%	5.00%	3.69%	5.49%
Effective Tax Rate	25.34%	27.34%	28.07%	38.39%	37.49%	25.49%

Source: S&P Capital IQ. Standard template. Financial Sources.